The impact of dietary calcium intake and vitamin D status on the effects of zoledronate

The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml

(2012) A. S. Carmel et al.   OSTEOPOROSIS INTERNATIONAL

Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial

(2011) Andrew Grey et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Prolonged antiresorptive activity of zoledronate: A randomized, controlled trial

(2010) Andrew Grey et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid

(2010) I. R. Reid et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Vitamin D insufficiency and health outcomes over 5 y in older women

(2009) Mark J Bolland et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion

(2009) Francesco Bertoldo et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women

(2008) Andrew Grey et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Vitamin D insufficiency does not affect response of bone mineral density to alendronate

(2008) D. M. Antoniucci et al.   OSTEOPOROSIS INTERNATIONAL

Vitamin D status and response to treatment in post-menopausal osteoporosis

(2008) S. Adami et al.   OSTEOPOROSIS INTERNATIONAL